Multicenter Study Results on Expanded Indications in Med-EL Pediatric Cochlear Implant Population

OBJECTIVES: To demonstrate safety and efficacy of MED-EL cochlear implants (CIs) in children aged < 12 months and in children aged 12-71 months with residual hearing.

Continue reading at PubMed →

If results confirm safety and efficacy in infants under 12 months and in children with residual hearing under expanded criteria, pediatric cochlear implant programs should review MED-EL candidacy guidelines accordingly — though independent replication and regulatory context should be considered before changing local protocols.

Expanding cochlear implant candidacy to younger infants and children with residual hearing could significantly improve long-term language outcomes for a broader population of children with hearing loss.

1. 01Multicenter study evaluated MED-EL cochlear implants in children under 12 months of age.
2. 02Also assessed children aged 12–71 months with residual hearing under expanded indications.
3. 03Safety and efficacy were the primary endpoints across both expanded groups.
4. 04Results support potential broadening of pediatric cochlear implant candidacy criteria.
5. 05Published in The Laryngoscope; study involves a specific manufacturer's device (MED-EL).

PMID

42619050

DOI

10.1002/lary.70840.

Journal

The Laryngoscope

Publication type

research_article

Evidence level

2b

Population

Children under 12 months of age and children aged 12–71 months with residual hearing receiving MED-EL cochlear implants

Intervention

MED-EL cochlear implantation under expanded indications